Today: 11 June 2026
AGL Energy share price falls 2.7% as ex-dividend day looms — what to watch next on the ASX
23 February 2026
1 min read

AGL Energy share price falls 2.7% as ex-dividend day looms — what to watch next on the ASX

Sydney, Feb 23, 2026, 18:47 AEDT — Market closed

  • AGL closed out Monday down 2.7%, settling at A$10.31.
  • The stock loses rights to the 24-cent interim dividend on Tuesday, as shares go ex-dividend.
  • Traders are eyeing Tuesday’s expected reset after a muted session, with attention turning to the rest of the tape.

AGL Energy Ltd (AGL.AX) slid 2.7% on Monday, closing at A$10.31 after losing 29 Australian cents during the session.

AGL will trade ex-dividend Tuesday, per its latest filing. The utility’s interim dividend stands at 24 Australian cents, fully franked, with shareholders on record as of Feb. 25 set to receive payment March 26.

The “ex-dividend” date is the cutoff—buy on or after it, and you miss out on the coming dividend. Stocks usually slip by about the same amount as the payout when the date hits, though the drop is almost never exact.

AGL shares took a hit as the Australian market pulled back, the S&P/ASX 200 falling 0.6%. Utilities led the way down; that sub-index shed about 1.0%.

AGL set its interim dividend on Feb. 11, posting underlying net profit after tax of $353 million for the first half. The company narrowed its FY26 underlying EBITDA forecast, now seeing $2.02 billion to $2.18 billion, with adjustments for items it categorizes as one-off. “The strength of our first half result was delivered by our excellent operational performance,” CEO Damien Nicks said. ASX Announcements

AGL has launched a $50 million cost-cutting plan, with management targeting the savings to fully take effect by FY27. Analysts at Sandstone Insights estimate the initiative amounts to slicing group costs by nearly 7%-8% after the company’s latest result.

The math’s straightforward Tuesday: a 24-cent dividend comes out to about 2.3% of Monday’s closing price. When the stock starts trading ex-dividend, seeing a dip of that magnitude wouldn’t raise eyebrows.

Dividends offer little shelter if the market turns against investors. If risk appetite stays subdued or power markets swing the wrong way for retailers, shares could tumble far below the dividend payout—leaving losses that stick.

Earnings remain unpredictable. Margins in the National Electricity Market can swing quickly—weather turns, a wholesale price spike, or a sudden network squeeze, any of these can flip the outlook fast.

Stock Market Today

  • TIG Advisors Reduces Stake in Beazley PLC by 330,000 Shares
    June 11, 2026, 10:47 AM EDT. TIG Advisors, LLC, acting as discretionary investment manager for AlTi Global, Inc., disclosed a reduction in its long position in Beazley PLC's shares. After the deal on June 10, 2026, it held 5,928,546 derivative shares, representing 0.99% of Beazley's total securities (ISIN: GB00BYQ0JC66). The transaction involved selling 330,000 5p ordinary shares at a price of 1,283.00 pence per unit. The disclosure was made under Rule 8.3 of the UK's Takeover Code, which requires revealing interests exceeding 1% in relevant securities. This transaction signals a strategic portfolio adjustment by TIG Advisors in the insurance firm's equity.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
Visa stock set for Monday as Mexico blocks Prosa deal after the bell
Previous Story

Visa stock set for Monday as Mexico blocks Prosa deal after the bell

CrowdStrike stock steadies premarket after Anthropic’s Claude Code Security rattles cyber shares
Next Story

CrowdStrike stock steadies premarket after Anthropic’s Claude Code Security rattles cyber shares

Go toTop